e-learning
resources
ERJ
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Should oral anticoagulation be discontinued after 3 months in the setting of a first high-risk pulmonary embolism secondary to a major transient/reversible risk factor?
Guy Meyer, Stavros Konstantinides
Source:
Eur Respir J, 55 (1) 1902323; 10.1183/13993003.02323-2019
Journal Issue:
January
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Guy Meyer, Stavros Konstantinides. Should oral anticoagulation be discontinued after 3 months in the setting of a first high-risk pulmonary embolism secondary to a major transient/reversible risk factor?. Eur Respir J, 55 (1) 1902323; 10.1183/13993003.02323-2019
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Emerging classes of drugs for the treatment of obstructive lung disease
Eosinophils and airway nerves in asthma
Related content which might interest you:
Risk factors for recurrences in patients with idiopathic pulmonary embolism after withdrawal of long-term anticoagulation
Source: Eur Respir J 2006; 28: Suppl. 50, 44s
Year: 2006
Mortality and recurrence during a follow-up of 2 years of pulmonary embolism: Role of anticoagulant therapy
Source: Annual Congress 2010 - Pulmonary embolism
Year: 2010
The incidence of venous thromboembolism recurrence in patients after first episode acute pulmonary embolism and related risk factors
Source: Annual Congress 2012 - Pulmonary circulation: clinical aspects of PAH, PTE and CTEPH
Year: 2012
Should thrombolysis and sildenafil be given in the acute management of patients with large pulmonary embolism? An assessment of the short and long-term outcomes.
Source: International Congress 2019 – Pulmonary embolism: from diagnosis to prognosis and treatment
Year: 2019
Risks of pulmonary thromboembolism associated with ambulatory management of clinically proven deep vein thrombosis
Source: Annual Congress 2005 - News about pulmonary embolism
Year: 2005
Early discharge of patients with pulmonary embolism: feasibility of domicillary anticoagulation
Source: Eur Respir J 2003; 22: Suppl. 45, 219s
Year: 2003
The outcome of anticoagulation alone therapy for patients with submassive pulmonary embolism
Source: International Congress 2019 – Epidemiology and management of acute pulmonary embolism
Year: 2019
Hestia criteria can discriminate high- from low-risk patients with pulmonary embolism
Source: Eur Respir J 2013; 41: 588-592
Year: 2013
Pulmonary angioplasty vs exclusive medical treatment in inoperable chronic thromboembolic hypertension–initial outcomes from a pulmonary hypertension centre
Source: Virtual Congress 2020 – Chronic thromboembolic pulmonary hypertension
Year: 2020
Successful pregnancy outcome in patients with pulmonary arterial hypertension receiving prostayclin therapy
Source: Annual Congress 2004 - Pulmonary hypertension
Year: 2004
Presence of bronchopulmonary shunting is an independent risk factor for recurrence of hemoptysis following bronchial artery embolization in younger patients with bronchiectasis: a long-term outcome
Source: International Congress 2019 – Highlights in lung function and chronic cough
Year: 2019
Outpatient treatment and early discharge of symptomatic pulmonary embolism: a systematic review
Source: Eur Respir J 2009; 33: 1148-1155
Year: 2009
Recommended uses for indefinite secondary prophylaxis in patients with pulmonary embolism
Source: Eur Respir J 2006; 28: Suppl. 50, 402s
Year: 2006
Prediction of bleeding events in patients with venous thromboembolism on stable anticoagulation treatment
Source: Eur Respir J 2016; 48: 1369-1376
Year: 2016
Efficacy of a 12 months oral sildenafil treatment in patients with severe pulmonary hypertension
Source: Eur Respir J 2006; 28: Suppl. 50, 660s
Year: 2006
A risk score of adverse short-term clinical outcomes in patients with acute pulmonary embolism (PE)
Source: Eur Respir J 2005; 26: Suppl. 49, 271s
Year: 2005
A case-control study on direct oral anticoagulants versus warfarin for acute pulmonary embolism in obese patients
Source: Virtual Congress 2021 – Insights into pulmonary embolism
Year: 2021
Direct oral anticoagulant therapy in patients with morbid obesity after intermediate- or high-risk pulmonary emboli
Source: ERJ Open Res, 7 (1) 00554-2020; 10.1183/23120541.00554-2020
Year: 2021
The evaluation of medication adherence in patients with pulmonary thromboembolism
Source: International Congress 2018 – Acute pulmonary embolism: from diagnosis to treatment
Year: 2018
Direct oral anticoagulant use and thrombus detection in patients with chronic thromboembolic pulmonary hypertension referred for pulmonary thromboendarterectomy
Source: International Congress 2019 – Chronic thromboembolic pulmonary hypertension
Year: 2019
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept